TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01343303

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet/capsule every 12 hours for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: 2 x 25 mg tablets once daily for 21 days
Study: NCT00908687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 Low Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 Low Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 High Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 High Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A/H5N1
Description: A/H5N1 High Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LT Adjuvant Patch
Description: LT Adjuvant Patch Low Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LT Adjuvant Patch
Description: LT Adjuvant Patch Low Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LT Adjuvant Patch
Description: LT Adjuvant Patch High Dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LT Adjuvant Patch
Description: LT Adjuvant Patch High Dose
Study: NCT01245062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212
Description: MEK inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Investigator Choice of DTIC or paclitaxel
Study: NCT04309630

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intercostal block
Description: pain control by intercostal block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spina plane block
Description: pain control by erector spina plane block
Study: NCT02845427

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: closed suction drain
Description: using closed suction drain system postoperative

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: no suction drain
Description: the surgical wound will be closed with no suction drain
Study: NCT04028960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular insulin (Humulin-R), intranasal route
Description: Humulin-R insulin is approved by the U.S. Food and Drug Administration (FDA) for the treatment of diabetes.
Study: NCT01343303

Intervention type: DRUG
Group type: OTHER
Intervention: Naproxen
Description: 500 mg capsule every 12 hours for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39439335
Description: 2 x 5 mg tablets once daily for 21 days
Study: NCT00712777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.2 %
Description: Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine 0.2 %
Description: Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
Study: NCT00206960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
Study: NCT01602952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radotinib
Description: 50mg, 100mg or 200mg Capsule BID
Study: NCT03665597

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose B
Description: IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Dose D
Description: IV infusion once every 6 weeks
Study: NCT00621491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Warfarin
Description: Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
Study: NCT05928156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myeloma Coach or CLL Coach Mobile App
Description: Symptom Tracking: Subjects will be asked to track their symptoms on a weekly basis, as well as given the opportunity to track these symptoms whenever they would like. Subjects will receive feedback tailored to their symptom severity with coaching on self management, including encouraging them to reach out to their health care team when symptoms are new, severe or increasing in severity. Subjects will also be able to look at graphs of symptom severity over time and share them with family and their health care team.~Medication Adherence Reminders and Tracking, Activities - tools based on CBT (cognitive behavioral therapy) principles can be utilized at any time to manage emotional distress. Learn - information on cancer, its treatment, self managing physical and emotional symptoms, and supportive resources.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Springboard Beyond Cancer informational website
Description: Springboard Beyond Cancer (https://survivorship.cancer.gov) is designed to make it easy for those in treatment and post-treatment to access essential information to help them manage ongoing cancer-related symptoms, deal with stress, improve healthy behaviors, communicate better with healthcare teams, and seek support from friends and family.
Study: NCT01961947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP7374
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: approved egg-derived TIV
Description: subcutaneous
Study: NCT00101647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
Study: NCT04410263

Intervention type: DIAGNOSTIC_TEST
Intervention: Sampling (EDTA blood, pharyngeal and nose swabs, bronchoalveolar lavage ,urine)
Description: Most data and part of the biological material required for addressing the research questions in this project are generated in the treatment of the patients. The following data and samples are collected specifically for this project according to the study schedule (i.e. extra sampling or additional questioning):~* blood samples (day 0= 40 ml EDTA, day 2= 20 ml EDTA, day 3= 30 ml EDTA, day 5=10 ml EDTA, every 5 days = 20 ml EDTA)~* Swabs (oral +/- nasal +/- nasopharyngeal)~* Sublingual microscopy
Study: NCT02601625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab SC injection (300mg)
Description: 300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab IV infusion (300mg)
Description: 300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
Study: NCT04028960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SipNose intranasal device
Description: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SipNose intranasal device
Description: The SipNose device is an aerosol nasal delivery platform that uses pressurized delivery through the discharge of compressed air, resulting in an aerosol that delivers the drug in a narrow plume geometry, which targets the olfactory epithelium in the upper nasal cavity. From the olfactory epithelium, therapeutics rapidly reach the central nervous system, traveling extracellularly along the olfactory nerves. The device is not currently commercially available, but numerous studies have demonstrated its ability to intranasally deliver radiolabeled and therapeutic compounds to the brain.
Study: NCT02668406

Intervention type: OTHER
Intervention: Venous blood sampling (2 timepoints) (Phase A and B)
Description: 8.5ml at Day 1 + 8.5ml at Day 5
Study: NCT02601625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anifrolumab SC infusion (600mg)
Description: 600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anifrolumab placebo SC injection (300mg)
Description: 300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anifrolumab placebo IV infusion (300mg)
Description: 600mg of placebo delivered as an IV infusion over 30 minutes on Day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Anifrolumab placebo SC infusion (600mg)
Description: 600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
Study: NCT01888523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday experiences writing
Description: log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
Study: NCT03797872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate up to 25mg/week as tolerated po or sc

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Sulfasalazine up to 3g daily po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide 10-20mg daily po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: For IA or IM injection 20-120mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: For IA or IM injection 20-120mg
Study: NCT04297891

Intervention type: OTHER
Intervention: Clinical rating scale to measure Ataxia disease severity and progression
Description: SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.

Intervention type: OTHER
Intervention: Clinical rating scale to measure Ataxia disease severity and progression
Description: SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.

Intervention type: OTHER
Intervention: Clinical rating scale to measure Ataxia disease severity and progression
Description: SARA is a clinical scale developed by Schmitz-Hübsch et al which assesses a range of different impairments in cerebellar ataxia. The scale is made up of 8 items related to gait, stance, sitting, speech, finger-chase test, nose-finger test, fast alternating movements and heel-shin test.

Intervention type: OTHER
Intervention: Clinical rating scale to measure spastic paraplegia disease severity and progression
Description: A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.

Intervention type: OTHER
Intervention: Clinical rating scale to measure spastic paraplegia disease severity and progression
Description: A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.

Intervention type: OTHER
Intervention: Clinical rating scale to measure spastic paraplegia disease severity and progression
Description: A 13-item scale to rate functional impairment occurring in pure forms of spastic paraplegia (SP). Additional symptoms constituting a complicated form of SP are recorded in an inventory.

Intervention type: OTHER
Intervention: Disease-specific severity index for adults with autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS)
Description: The DSI-ARSACS is a valid measure of disease severity for the adult ARSACS population that is able to distinguish between patients with different clinical profiles.~It considers the 3 components (pyramidal, cerebellar, neuropathic) of the disease, and documents its content validity, internal consistency, and construct validity.
Study: NCT01938183

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth periodontal debridement
Description: full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full-mouth periodontal debridement
Description: full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Full-mouth periodontal debridement
Description: full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole tablet
Description: 750 mg metronidazole tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: semi-solid suspension containing carbopol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole benzoate gel
Description: 15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
Study: NCT03529656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early rehabilitation program for liver transplantation
Description: Deliver the one of 5-step early rehabilitation program for immediate liver transplant pts on weekday
Study: NCT04957888

Intervention type: OTHER
Intervention: none intervention
Description: none intervention.

Intervention type: OTHER
Intervention: none intervention
Description: none intervention.
Study: NCT00817414

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching placebo
Description: LCI699-matching placebo oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules
Study: NCT01503021

Intervention type: DRUG
Group type: OTHER
Intervention: SFP
Description: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate

Intervention type: DRUG
Group type: OTHER
Intervention: SFP
Description: Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Dialysis with standard liquid bicarbonate concentrate without iron

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Dialysis with standard liquid bicarbonate concentrate without iron
Study: NCT01802944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Study: NCT01160731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study: NCT05556018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Activation Mapping Guided Cardiac resynchronization therapy
Description: To study the feasibility to optimize configuration of CRT delivery for acute correction of electrical dyssynchrony using a noninvasive mapping of global electrical activation
Study: NCT05208320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence
Description: Patients received interventions as follow:~* The health education syllabus included 4 chapters: (1) introduction to hypertension, (2) complications of high blood pressure, (3) lifestyle management, and (4) SCORE - European High-Risk Chart~* Home health education by Community Health Workers every month for 6 months
Study: NCT00954538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]MK-3328
Description: IV dose of \~150 megabecquerel (MBq) \[18F\]MK-3328
Study: NCT02249780

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative parathyroid function test
Description: Calcium and parathormone dosage at 24 hours and ten day after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No postoperative parathyroid dosage and supplementation
Description: The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICG parathyroid angiography
Description: Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICG parathyroid angiography
Description: Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parathyroid supplementation
Description: Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
Study: NCT02487199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir
Study: NCT01088893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
Study: NCT02475447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asimadoline
Description: kappa-opioid receptor agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo-matched control
Study: NCT03800108

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Personalized DBS adjustments
Description: Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs
Study: NCT00744198

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous transobturator tape procedure
Description: A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Synthetic transobturator tape procedure
Description: Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biological transobturator tape procedure
Description: Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
Study: NCT04344093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patch validation
Description: Use of connected patch to collect blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature
Study: NCT00667966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY 38-9456), 10 mg
Description: 10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY 38-9456), 10 mg
Description: 10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10/20 mg placebo in sequence in respective arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10/20 mg placebo in sequence in respective arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY 38-9456), 20 mg
Description: 20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil (Levitra, BAY 38-9456), 20 mg
Description: 20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
Study: NCT00369018

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
Description: MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
Description: MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
Description: MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
Description: MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
Description: MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)
Description: MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
Study: NCT02302456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin